Strata Oncology, Inc., a precision oncology company, today announced the launch of its 2.0 test, StrataNGS, a custom-designed, 90-gene targeted assay focused on actionable genetic alterations in tumor tissue, including standard of care markers and clinical trial eligibility markers.

The StrataNGS test offers enhanced capabilities (4x larger DNA panel, 3x larger RNA panel), while maintaining a turnaround time of less than 10 business days and without increasing input requirements. It sequences DNA and RNA in archival or fresh biopsy tissue, and assays for specific predefined single nucleotide variants, multinucleotide variants, small insertions and deletions (indels), gene fusions, exon skipping mutations and copy number changes, as well as for de novo deleterious mutations (stop gains and frame shifting indels) in tumor suppressor genes.

In addition, the StrataNGS test measures expression levels for several emerging immuno-oncology biomarkers. Although these biomarkers are not yet reported clinically, the data will be available to Strata for correlative analyses and future test expansion. 

“Strata Oncology is dramatically expanding patient access to tumor sequencing and precision medicine trials, and accelerating the approval of important targeted therapies,” said Dan Rhodes, Ph.D., CEO of Strata Oncology. “The StrataNGS test is one critical piece in our integrated model. We are pleased to move quickly in adapting our testing capabilities, and anticipating the needs of researchers and clinicians.”

Testing is performed in Strata Oncology’s fully automated, high-throughput CLIA-certified lab in Ann Arbor, Michigan.